Chromatin Bioscience Signs Collaboration Agreement with Astellas
Under the agreement, Chromatin Bioscience will use its proprietary chromatinLENS platform to design cell-selective synthetic promoters aligned with Astellas' target profile. The designed promoters are expected to enable highly precise and durable gene expression in specific cell types.
"We're excited to begin this collaboration with Astellas," said
Chromatin Bioscience's chromatinLENS platform enables the identification of gene regulatory elements from the dark genome and the rational design of synthetic promoters tailored to specific applications. The platform can be applied across a range of sectors—including therapeutics, agritech, industrial biotechnology, and bioprocessing. The collaboration with Astellas further validates the potential of the chromatinLENS platform and represents the latest milestone in a series of collaborations that are shaping Chromatin's continued growth and impact.
For more information about Chromatin Bio's recent collaborations, visit https://www.chromatinbio.com/news
Notes to Editors
About Chromatin Bioscience
Chromatin Bioscience is a biotechnology company focused on the design and development of synthetic promoters for targeted gene control systems. Its proprietary platform enables precise, cell-type-selective, and durable gene expression, which is key to advancing the next generation of therapeutics, bioproduction systems and agritech innovations. Chromatin's synthetic promoters have been integral to a growing number of client programs. For more information, visit www.chromatinbio.com.
Logo - https://mma.prnewswire.com/media/2598726/5255592/Chromatin_Bioscience_Logo.jpg
View original content to download multimedia:https://www.prnewswire.com/news-releases/chromatin-bioscience-signs-collaboration-agreement-with-astellas-302423204.html
SOURCE Chromatin Bioscience
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Cove Capital Investments Continues to Expand Its Delaware Statutory Trust Portfolio with the Acquisition of Its Cove San Antonio Multifamily 119 DST - a 170-Unit Multifamily Community
- PLT Health Solutions Science Team to Present Three Posters at Nutrition 2026 Conference
- STANDEX ANNOUNCES TIMING OF FOURTH QUARTER FISCAL 2026 RESULTS
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share